PUBLISHER: Grand View Research | PRODUCT CODE: 1301042
PUBLISHER: Grand View Research | PRODUCT CODE: 1301042
Bispecific Antibodies Market Size, Share & Trends Analysis Report By Indication (Cancer, Inflammatory & Autoimmune disorders), By Region (North America, Europe, Asia Pacific), And Segment Forecasts, 2023 - 2030
Bispecific Antibodies Market Growth & Trends
The global bispecific antibodies market size is expected to reach USD 110.3 billion by 2030, expanding at a CAGR of 44.0% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancers such as breast cancer, lung cancer, prostate cancer, and other chronic diseases is a major driver for market growth. These molecules provide a targeted approach to treat specific types of cancer by simultaneously targeting cancer cells and the immune system. Additionally, the rising demand for personalized medicine and the shift toward targeted therapies have contributed to the market's growth.
Moreover, collaborations and partnerships between pharmaceutical companies and biotechnology firms have played a crucial role in advancing bispecific antibody research and development. These collaborations have accelerated the discovery and clinical development of novel bispecific antibodies, further propelling the market growth. For instance, in January 2022, Amgen and Generate Biomedicines established a research partnership agreement to discover and develop protein therapies for five clinical targets spanning different therapeutic areas and modalities. In addition to it, in May 2023, The U.S. FDA approved EPKINLY (epcoritamab-bysp) as the inaugural bispecific antibody to be authorized for the treatment of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) in adult patients.
The COVID-19 pandemic has had a dual impact on the bispecific antibodies industry. On one hand, it has underscored the significance of bispecific antibodies in addressing infectious diseases. However, the pandemic has also introduced challenges in the form of supply chain disruptions, leading to delays in the research and development of bispecific antibodies. Furthermore, economic uncertainties and budget constraints have affected research institutions and biotech companies, potentially influencing their prioritization and allocation of resources towards bispecific antibody development.
Furthermore, various developments undertaken by participants, and increasing industry-academia collaborations have driven the global market to a significant extent. For instance, in March 2023, Thermo Fisher Scientific Inc collaborated with Arsenal Bioscience, a cell therapy company to facilitate and support the clinical manufacturing of Autologous T-Cell Therapies.
Bispecific Antibodies Market Report Highlights
- By indication, the cancer segment dominated the market with a share of 70.4% in 2022, due high prevalence of cancer globally. Furthermore, bispecific antibodies specifically target tumor cells or tumor-associated antigens while sparing healthy cells
- Inflammatory and autoimmune disorders segment is expected to grow at a significant CAGR of 35.7% during 2023-2030, owing to the increasing adoption and development of bispecific antibody drugs for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, and multiple sclerosis among others.
- North America established a strong regional position in the global market with an 89.5% share in 2022 due to its highly developed healthcare infrastructure and favorable government policies
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Information Procurement
- 1.2. Information Or Data Analysis
- 1.3. Market Scope & Segment Definition
- 1.4. Market Model
- 1.4.1. Market Study, By Company Market Share
- 1.4.2. Regional Analysis
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Growing prevalence of chronic diseases
- 3.2.1.2. Increasing investment in biologics research and development
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High development cost
- 3.2.1. Market Driver Analysis
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
- 3.4. Pipeline Analysis
Chapter 4. Indication Business Analysis
- 4.1. Bispecific Antibodies Market: Indication Movement Analysis
- 4.2. Cancer
- 4.2.1. Cancer Market, 2018 - 2030 (USD Million)
- 4.3. Inflammatory & Autoimmune Disorders
- 4.3.1. Inflammatory & Autoimmune Disorders Market, 2018 - 2030 (USD Million)
- 4.4. Others
- 4.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Regional Business Analysis
- 5.1. Bispecific Antibodies Market Share By Region, 2022 & 2030
- 5.2. North America
- 5.2.1. North America Bispecific Antibodies Market, 2018 - 2030 (USD Million)
- 5.2.2. The U.S.
- 5.2.2.1. Key Country Dynamics
- 5.2.2.2. Target Disease Prevalence
- 5.2.2.3. Competitive Scenario
- 5.2.2.4. Regulatory Framework
- 5.2.2.5. U.S. Bispecific Antibodies Market, 2018 - 2030 (USD Million)
- 5.2.3. Canada
- 5.2.3.1. Key Country Dynamics
- 5.2.3.2. Target Disease Prevalence
- 5.2.3.3. Competitive Scenario
- 5.2.3.4. Regulatory Framework
- 5.2.3.5. Canada Bispecific Antibodies Market, 2018 - 2030 (USD Million)
- 5.3. Europe
- 5.3.1. Europe Bispecific Antibodies Market, 2018 - 2030 (USD Million)
- 5.3.2. UK
- 5.3.2.1. Key Country Dynamics
- 5.3.2.2. Target Disease Prevalence
- 5.3.2.3. Competitive Scenario
- 5.3.2.4. Regulatory Framework
- 5.3.2.5. UK Bispecific Antibodies Market, 2018 - 2030 (USD Million)
- 5.3.3. Germany
- 5.3.3.1. Key Country Dynamics
- 5.3.3.2. Target Disease Prevalence
- 5.3.3.3. Competitive Scenario
- 5.3.3.4. Regulatory Framework
- 5.3.3.5. Germany Bispecific Antibodies Market, 2018 - 2030 (USD Million)
- 5.4. Asia Pacific
- 5.4.1. Asia Pacific Bispecific Antibodies Market, 2018 - 2030 (USD Million)
- 5.4.2. Japan
- 5.4.2.1. Key Country Dynamics
- 5.4.2.2. Target Disease Prevalence
- 5.4.2.3. Competitive Scenario
- 5.4.2.4. Regulatory Framework
- 5.4.2.5. Japan Bispecific Antibodies Market, 2018 - 2030 (USD Million)
- 5.4.3. China
- 5.4.3.1. Key Country Dynamics
- 5.4.3.2. Target Disease Prevalence
- 5.4.3.3. Competitive Scenario
- 5.4.3.4. Regulatory Framework
- 5.4.3.5. China Bispecific Antibodies Market, 2018 - 2030 (USD Million)
- 5.5. Rest of the world
- 5.5.1. Rest of the world Bispecific Antibodies Market, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Company Categorization
- 6.2. Strategy Mapping
- 6.3. Company Market Share Analysis, 2022
- 6.4. Company Profiles/Listing
- 6.4.1. Amgen
- 6.4.1.1. Overview
- 6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.1.3. Product Benchmarking
- 6.4.1.4. Strategic Initiatives
- 6.4.2. Roche
- 6.4.2.1. Overview
- 6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.2.3. Product Benchmarking
- 6.4.2.4. Strategic Initiatives
- 6.4.3. Genentech
- 6.4.3.1. Overview
- 6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.3.3. Product Benchmarking
- 6.4.3.4. Strategic Initiatives
- 6.4.4. Akeso, Inc
- 6.4.4.1. Overview
- 6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.4.3. Product Benchmarking
- 6.4.4.4. Strategic Initiatives
- 6.4.5. Janssen
- 6.4.5.1. Overview
- 6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.5.3. Product Benchmarking
- 6.4.5.4. Strategic Initiatives
- 6.4.6. Taisho Pharmaceutical
- 6.4.6.1. Overview
- 6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.6.3. Product Benchmarking
- 6.4.6.4. Strategic Initiatives
- 6.4.7. Immunocore
- 6.4.7.1. Overview
- 6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.7.3. Product Benchmarking
- 6.4.7.4. Strategic Initiatives
- 6.4.1. Amgen
List of Tables
- TABLE 1. List of abbreviations
- TABLE 2. Global bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
- TABLE 3. North America bispecific antibodies market, by country, 2018 - 2030 (USD Million)
- TABLE 4. North America bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
- TABLE 5. U.S. bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
- TABLE 6. Canada bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
- TABLE 7. Europe bispecific antibodies market, by country, 2018 - 2030 (USD Million)
- TABLE 8. Europe bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
- TABLE 9. UK bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
- TABLE 10. Germany bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
- TABLE 11. Asia Pacific bispecific antibodies market, by country, 2018 - 2030 (USD Million)
- TABLE 12. Japan bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
- TABLE 13. China bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
- TABLE 14. Rest of World bispecific antibodies market, by country, 2018 - 2030 (USD Million)
List of Figures
- FIG. 1 Market research process
- FIG. 2 Information procurement
- FIG. 3 Primary research pattern
- FIG. 4 Market research approaches
- FIG. 5 Value chain-based sizing & forecasting
- FIG. 6 Market formulation & validation
- FIG. 7 Bispecific Antibodies market segmentation
- FIG. 8 Market snapshot, 2022
- FIG. 9 Market trends & outlook
- FIG. 10 Market driver relevance analysis (current & future impact)
- FIG. 11 Market restraint relevance analysis (current & future impact)
- FIG. 12 PESTEL analysis
- FIG. 13 Porter's five forces analysis
- FIG. 14 Global bispecific antibodies market: Indication movement analysis
- FIG. 15 Global bispecific antibodies market, for cancer, 2018 - 2030 (USD Million)
- FIG. 16 Global bispecific antibodies market, for Inflammatory & Autoimmune Disorders, 2018 - 2030 (USD Million)
- FIG. 17 Global bispecific antibodies market, for others 2018-2030, (USD Million)
- FIG. 18 Global bispecific antibodies market: Region movement analysis
- FIG. 19 North America bispecific antibodies market, 2018 - 2030 (USD Million)
- FIG. 20 U.S. bispecific antibodies market, 2018 - 2030 (USD Million)
- FIG. 21 Canada bispecific antibodies market, 2018 - 2030 (USD Million)
- FIG. 22 Europe bispecific antibodies market, 2018 - 2030 (USD Million)
- FIG. 23 Germany bispecific antibodies market, 2018 - 2030 (USD Million)
- FIG. 24 UK bispecific antibodies market, 2018 - 2030 (USD Million)
- FIG. 25 Asia Pacific bispecific antibodies market, 2018 - 2030 (USD Million)
- FIG. 26 Japan bispecific antibodies market, 2018 - 2030 (USD Million)
- FIG. 27 China bispecific antibodies market, 2018 - 2030 (USD Million)
- FIG. 28 Rest of the World bispecific antibodies market, 2018 - 2030 (USD Million)
